Cybin Inc.

About

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics™ by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

Drug Development:

‍ Cybin has three drug development programs (CYB003, CYB004 & CYB005)
‍
• CYB003 (Deuterated Tryptamine) for Alcohol Use Disorder (AUD) and Major Depressive Disorder (MDD). Phase 1/2a initiation is expected mid-2022.
‍
• CYB004 (Deuterated dimethyltryptamine, or DMT) for Anxiety Disorders through inhalation delivery. Pilot study initiation is expected in 3Q2022.
‍
• CYB005 (Phenethylamine) for neuroinflammation.  

Partnerships

Through a partnership with Kernel, Cybin is leveraging Kernel Flow, a breakthrough neuroimaging technology that provides real time, qualitative data during a patient’s psychedelic experience. Cybin expects to begin a Phase 1 Kernel Flow feasibility study in 1Q 2022.

Cybin has developed a pipeline of nearly 50 different proprietary psychedelic molecules based upon DMT, MDMA, Psilocybin and other analogueso  Cybin is building a portfolio of proprietary deuterated molecules which  have improved pharmacokinetic profiles, while retaining the efficacy of the original molecule and that will result in more scalable treatments as compared to its peers.

• Cybin has been granted a patent by the USPTO that protects CYB004 (deuterated DMT) as a putative new chemical entity, and also covers a range of deuterated forms of DMT and 5-MeO-DMT.
‍
• To date Cybin has completed over 140 pre-clinical studies on a portion of its molecules within its discovery pipeline.  These studies have been conducted both in vitro and in vivo with promising results allowing for full IND enabling studies on certain molecules.
‍
• Cybin’s development thesis is based on the need to create commercially viable drugs to meet the needs of patients and to easily integrate into the existing medical eco-system .

Management Team

Doug Drysdale, Chief Executive Officer

• An experienced Corporate Director and CEO: Doug has chaired the
  board of directors of a NASDAQ-listed company and, as a CEO for
  the past 12 years, has built and turned-around 3 pharmaceutical
  companies.
  ‍
• During Doug’s 30 years of experience in the healthcare sector, he
  has formed cohesive management teams, recruited board members,
  completed 15 corporate acquisitions across three continents and
  has raised $4 billion of both public and private capital.
  ‍
• Led the turnaround of Norwich Pharmaceuticals alongside
  investors and became the Founding CEO of parent company,
  Alvogen Group. During his 5.5-year tenure as CEO, Alvogen grew
  from inception to $450 million in revenues across 35 countries.
  ‍
• From November 2017 to July 2020, Doug was a Director and CEO
  of Tedor Pharma, a family-owned contract manufacturing business.
  Doug’s efforts to turnaround the business resulted in 60% revenue
  growth in 2019, leading to Tedor being recognized as one of
  America’s fastest-growing companies, making it to the 2020 Inc
  5000 list.

Dr. Alex Nivorozhkin, Chief Science Officer

• Lead NCE inventor of multiple successfully partnered drug discovery and
  development programs.
  ‍
• Technology developer of the proprietary formulations for CNS drugs.
  ‍
• Seasoned medicinal chemist, drug delivery expert and founder of multiple biotech
  companies.

Brett Greene, Chief Innovation Officer

• Research Administrator for the Center for Drug Discovery (one of the top
  Cannabinoid and Serotonin research centers in the world) for over a decade.
  ‍
• Co-managed $80M + in federal funding for cannabinoid and serotonin research.
  ‍
• Recognized leader in Psychedelics (co-founder, Psymposia)
  ‍
• Co-managed the NIDA-sponsored Chemistry & Pharmacology of Drug Abuse
  (CPDA) conference for 5 years

Dr. Michael Palfreyman, Chief R&D Officer

• 30 years of preclinical/clinical development experience: Scriptgen, EnVivo
  Pharma, Sanofi, GSK, Amorsa Therapeutics, and others.
  ‍
• Successfully led multiple IND filings and clinical programs.

• Significant portfolio of CNS therapeutics patents and commercial products.

‍
Dr. Alex Belser, Chief Clinical Advisor

• Licensed psychologist, clinical supervisor, and psychedelic researcher at Yale in
  psilocybin clinical trials.
  ‍
  
• Active in the psychedelic research community for 20 years.
  
  
• Conducted clinical research with psilocybin and MDMA for a variety of indications.
  ‍
  
• Research featured on front page of the NYT, in the Atlantic, the New Yorker, The
  Guardian, VICE, and in Michael Pollan's book, How to Change Your Mind.